Letter to Editor regarding “Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?”
- 16 August 2024
- journal article
- letter
- Published by Springer Nature in Osteoporosis International
- Vol. 35 (11) , 1-2
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?Osteoporosis International, 2024
- Italian position paper ( SIPMO‐SICMF ) on medication‐related osteonecrosis of the jaw ( MRONJ )Oral Diseases, 2024
- Joint report SIPMO-SIOMMMS sulla MRONJ in pazienti in cura con antiriassorbitivi per prevenire la CTIBLDental Cadmos, 2024
- MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case seriesBMC Oral Health, 2023
- Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single Center Retrospective Cohort StudyOral, 2022
- American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 UpdateJournal of Oral and Maxillofacial Surgery, 2022
- Bone health in cancer: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2020
- Workshop of European task force on medication‐related osteonecrosis of the jaw—Current challengesOral Diseases, 2019